Literature DB >> 3850854

Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections.

H Portier, A Kazmierczak, F Lucht, J C Tremeaux, P Chavanet, J M Duez.   

Abstract

Methicillin-resistant staphylococci (M-R staphylococci) represent 30% of the staphylococcal strains isolated in our hospital and pose important therapeutic problems. In a preliminary in vitro checkerboard study the bactericidal effect of various cephalosporins (cephalothin, cefamandole, cefotaxime and cefoperazone) in combination with other antibiotics (netilmicin, amikacin, vancomycin and fosfomycin) was studied on ten M-R staphylococcal strains. The combinations of cefoperazone with amikacin, cephalothin with vancomycin and of the four cephalosporins with fosfomycin were synergistic on the ten strains (FBC indexes less than or equal to 0.75). According to the CSF and bone levels achieved by these antibiotics and their bactericidal concentrations in combination, the combination of cefotaxime and fosfomycin was the most interesting, a concentration of less than or equal to 2 mg/l cefotaxime being bactericidal on five homogeneous M-R Staphylococcus aureus when combined with 4 mg/l of fosfomycin. This combination of cefotaxime (25 mg/kg, i.v. infusion over 30 min) and fosfomycin (50 mg/kg, i.v. infusion over three hours) three to four times daily was used to treat 16 patients: three patients with meningitis, six with bone and joint infections and seven with persistent bacteremia. The FBC indexes were less than or equal to 0.625 for the 12 strains studied. All the patients were cured without relapses. The concentrations of cefotaxime, desacetyl cefotaxime and fosfomycin in the CSF during meningitis three hours after the end of the infusion on the second day of treatment were 8.76, 6.82 and 58.0 mg/l, respectively, for patient one and 2.0, 0.53 and 31.0 mg/l, respectively, for patient two.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3850854     DOI: 10.1007/bf01644232

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Clinical, epidemiologic and bacteriologic observations of an outbreak of methicillin-resistant Staphylococcus aureus at a large community hospital.

Authors:  J J Klimek; F J Marsik; R C Bartlett; B Weir; P Shea; R Quintiliani
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

2.  2"-O-phosphorylation of gentamicin components by a Staphylococcus aureus strain carrying a plasmid.

Authors:  A Martel; N Moreau; M L Capmau; C J Soussy; J Duval
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

3.  Clinical pharmacology of cefotaxime including penetration into bile, sputum, bone and cerebrospinal fluid.

Authors:  J Kosmidis; C Stathakis; K Mantopoulos; T Pouriezi; B Papathanassiou; G K Daikos
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies.

Authors:  K Crossley; D Loesch; B Landesman; K Mead; M Chern; R Strate
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

5.  Treatment of infections due to methicillin-resistant Staphylococcus aureus.

Authors:  C Watanakunakorn
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

6.  Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections.

Authors:  J Klastersky; L Coppens; P van der Auwera; F Meunier-Carpentier
Journal:  J Antimicrob Chemother       Date:  1983-04       Impact factor: 5.790

7.  Bacteremia due to methicillin-resistant Staphylococcus aureus.

Authors:  J P Myers; C C Linnemann
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

8.  Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis.

Authors:  T Sicilia; E Estévez; A Rodríguez
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

9.  Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus.

Authors:  D E Craven; N R Kollisch; C R Hsieh; M G Connolly; W R McCabe
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  [Diffusion of fosfomycin into bone tissue in man].

Authors:  J Sirot; R Lopitaux; C Dumont; S Rampon; R Cluzel
Journal:  Pathol Biol (Paris)       Date:  1983-06
View more
  13 in total

1.  High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  José M Miró; José M Entenza; Ana Del Río; Maria Velasco; Ximena Castañeda; Cristina Garcia de la Mària; Marlyse Giddey; Yolanda Armero; Juan M Pericàs; Carlos Cervera; Carlos A Mestres; Manuel Almela; Carlos Falces; Francesc Marco; Philippe Moreillon; Asuncion Moreno
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Characterization of resistance phenotype and cephalosporin activity in oxacillin-resistant Staphylococcus aureus.

Authors:  M Mateos-Mora; C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 4.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

5.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

Review 7.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

8.  The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis.

Authors:  Cristina García-de-la-Mària; Oriol Gasch; Javier García-Gonzalez; Dolors Soy; Evelyn Shaw; Juan Ambrosioni; Manel Almela; Juan M Pericàs; Adrián Tellez; Carlos Falces; Marta Hernandez-Meneses; Elena Sandoval; Eduard Quintana; Barbara Vidal; Jose M Tolosana; David Fuster; Jaume Llopis; Miquel Pujol; Asuncion Moreno; Francesc Marco; Jose M Miró
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

9.  Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

Authors:  A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

10.  Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; J Lora-Tamayo; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.